89Sr adjuvant therapy in painful bone metastases of prostate cancer

1998 ◽  
Vol 147 (1) ◽  
pp. 6-7
Keyword(s):  
Prostate Cancer ◽  
Adjuvant Therapy ◽  
Bone Metastases ◽  
Painful Bone Metastases

Breast cancer patients have better outcomes than prostate cancer patients for palliation of painful bone metastases: Results of RTOG 97–14

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 6073-6073
Author(s):  
W. F. Hartsell ◽  
K. Winter ◽  
D. W. Bruner ◽  
C. W. Scarantino ◽  
R. Ivker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Painful Bone Metastases

Procollagen-I-propeptide and β-crosslaps are prognostic markers for pretherapeutic estimation of treatment success of combined radio- and bisphosphonate therapy in patients with bone metastases—A phase-II study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9096-9096 ◽  
Author(s):  
W. Wagner ◽  
A. Radmard ◽  
M. Bach ◽  
C. Loitsch ◽  
M. G. Krukemeyer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pain Relief ◽  
Bone Metastases ◽  
Treatment Success ◽  
Bisphosphonate Therapy ◽  
Dose Fractionation ◽  
Normal Range ◽  
Before And After ◽  
Breast And Prostate Cancer ◽  
Painful Bone Metastases

9096 Background: Multiple painful bone metastases are a common problem in patients suffering from breast and prostate cancer. Side effects of morphines can impair quality of life. Pain reduction can also be achieved by radiotherapy combined with bisphosphonates; however, this treatment is not successful in all patients. Methods: 35 patients with breast and prostate cancer suffering from painful bone metastases (multiple metastases in 29 cases, solitary metastasis in 6 cases: were locally irradiated (30 - 40 Gy over 3 - 4 weeks, conventional dose fractionation). In addition they received a bisphosphonate therapy (zoledronate). Before and after radiotherapy procollagen-I- propeptide and β-crosslaps were measured as parameters for the intensity of bone metabolism. Results: 24 patients experienced complete pain relief, 10 patients partial pain relief and one patient noticed no effect of treatment. The values of procollagen-I-propeptide (normal range 19–102 μg/l) and β-crosslaps (normal range <= 1,0 μg/l) were correlated with treatment success. At pretherapeutical procollagen-I- propeptide levels above 190 μg/l, all patients became entirely free of pain. All patients with β-crosslaps values above 0.5 μg/l became equally free of pain, irrespective of the number of metastases and tumour entity. The mean levels of procollagen-I-propeptide as well as β-crosslaps correlate directly and without exception with analgesia, reduction of pain or persistency of pain as final results. No correlation concerning the values was found before and after therapy. Conclusion: Procollagen-I-propeptide as well as β-crosslaps measurements before the beginning of a radio- and bisphosphonate therapy due to painful bone metastases are an excellent prognostic parameter to predict the success of therapy. Where high initial values (procollagen-I-propeptide > 190 μg/l or β-crosslaps > 0.5 μg/l) were measured, complete analgesia was achieved through therapy. Despite this clinically clear statement, a statistical significance with a t-Test was not evaluable at the current collection of patient data. Therefore, 20 more patients were examined; the results are yet to come. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document